Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Dexcom (DXCM) Stock Price & Analysis
3,249 Followers
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$74.75 - $142.00
Previous Close$111.66
Volume2.27M
Average Volume (3M)2.73M
Market Cap
$44.41B
Enterprise Value$46.37B
Total Cash (Recent Filing)$566.30M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)72.1
Beta1.16
Next Earnings
Jul 25, 2024EPS Estimate
$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.55
Shares Outstanding397,683,837
10 Day Avg. Volume2,830,334
30 Day Avg. Volume2,727,086
Standard Deviation0.15
R-Squared0.19
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)24.30
Price to Sales (P/S)12.81
Price to Cash Flow (P/CF)86.80
P/FCF Ratio134.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.80
Enterprise Value/Gross Profit20.26
Enterprise Value/Ebitda50.45
Forecast
1Y Price Target
$150.47Price Target Upside34.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Dexcom News
PremiumMarket News
QQQ ETF Update, 7/15/2024 
PremiumMarket News
QQQ ETF Update, 7/11/2024 
PremiumMarket News
QQQ ETF Update, 7/9/2024
PremiumMarket News
QQQ ETF Update, 7/4/2024 
PremiumMarket News
QQQ ETF Update, 7/2/2024 
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDXCM reported 1Q24 sales of $921MM, a 25% organic increase, and raised the low end of FY24 guidance to $4.20-4.35 billion, reflecting 17-21% growth.
Market ExpansionDXCM is expanding its US sales force by approximately 150 this year after doubling it in '21, tending to expand ahead of big new opportunities like Stelo.
Product LaunchStelo is the first FDA-cleared glucose biosensor available without a prescription.
Bears Say
Financial PerformanceGross margins compressed to 61.8% from 63.4% y/y.
Operating MarginStelo's margin impact will ultimately depend on pricing but DXCM expects the ramp to be dilutive to operating margin in 2024.
Revenue ExpectationsInvestors interpreted comments about U.S. sales realignment as a signal that Q2 revenue may disappoint, and shares quickly dropped 7%.
---
Ownership Overview
2.81% Insiders
35.07% Mutual Funds
26.09% Other Institutional Investors
36.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $74.75 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 25, 2024 which is in 3 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 25, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.39.
How many shares outstanding does Dexcom have?
Dexcom has 397,683,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.32 in its last earnings report, beating expectations of $0.27. Following the earnings report the stock price went down -9.905%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 2B.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$150.47 (34.76% Upside)
$150.47 (34.76% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 87%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.44%
12-Months-Change
Fundamentals
Return on Equity
28.54%
Trailing 12-Months
Asset Growth
17.52%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q1 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$150.47
▲(34.76% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
16/21 ratings generated profit
1 Year Average Return
+33.47%
reiterated a buy rating 10 days ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +33.47% per trade.
---